These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29750673)

  • 1. Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study.
    Lombardi G; Bergo E; Del Bianco P; Bellu L; Pambuku A; Caccese M; Trentin L; Zagonel V
    Am J Clin Oncol; 2018 Dec; 41(12):1263-1271. PubMed ID: 29750673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
    Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
    J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
    Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
    Minniti G; Scaringi C; Baldoni A; Lanzetta G; De Sanctis V; Esposito V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):285-91. PubMed ID: 23642624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
    Taphoorn MJ; Stupp R; Coens C; Osoba D; Kortmann R; van den Bent MJ; Mason W; Mirimanoff RO; Baumert BG; Eisenhauer E; Forsyth P; Bottomley A; ; ;
    Lancet Oncol; 2005 Dec; 6(12):937-44. PubMed ID: 16321761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
    Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
    J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
    Reddy K; Gaspar LE; Kavanagh BD; Waziri A; Damek DM; Ney D; Lillehei KO; Chen C
    J Neurooncol; 2013 Aug; 114(1):111-6. PubMed ID: 23729276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
    Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
    JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
    Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
    Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit and outcome of using temozolomide-based chemoradiotherapy followed by temozolomide alone for glioblastoma in clinical practice.
    Salma S; Djan I; Bjelan M; Vulekovic P; Novakovic M; Vidovic V; Lucic M
    J BUON; 2017; 22(5):1233-1239. PubMed ID: 29135107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
    Fabbro-Peray P; Zouaoui S; Darlix A; Fabbro M; Pallud J; Rigau V; Mathieu-Daude H; Bessaoud F; Bauchet F; Riondel A; Sorbets E; Charissoux M; Amelot A; Mandonnet E; Figarella-Branger D; Duffau H; Tretarre B; Taillandier L; Bauchet L
    J Neurooncol; 2019 Mar; 142(1):91-101. PubMed ID: 30523606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignancy Index Using Intraoperative Flow Cytometry is a Valuable Prognostic Factor for Glioblastoma Treated With Radiotherapy and Concomitant Temozolomide.
    Saito T; Muragaki Y; Shioyama T; Komori T; Maruyama T; Nitta M; Yasuda T; Hosono J; Okamoto S; Kawamata T
    Neurosurgery; 2019 Mar; 84(3):662-672. PubMed ID: 29618055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
    Osoba D; Brada M; Yung WK; Prados M
    J Clin Oncol; 2000 Apr; 18(7):1481-91. PubMed ID: 10735896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study.
    Altwairgi AK; Alghareeb WA; AlNajjar FH; Alhussain H; Alsaeed E; Balbaid AAO; Aldanan S; Orz Y; Alsharm AA
    Invest New Drugs; 2021 Feb; 39(1):226-231. PubMed ID: 32851510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
    Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
    J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
    Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
    Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
    Behm T; Horowski A; Schneider S; Bock HC; Mielke D; Rohde V; Stockhammer F
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2142-6. PubMed ID: 23993314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
    Laprie A; Ken S; Filleron T; Lubrano V; Vieillevigne L; Tensaouti F; Catalaa I; Boetto S; Khalifa J; Attal J; Peyraga G; Gomez-Roca C; Uro-Coste E; Noel G; Truc G; Sunyach MP; Magné N; Charissoux M; Supiot S; Bernier V; Mounier M; Poublanc M; Fabre A; Delord JP; Cohen-Jonathan Moyal E
    BMC Cancer; 2019 Feb; 19(1):167. PubMed ID: 30791889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.